Percheron Therapeutics secured $2.2 million to fuel its HMBD-002 oncology program, received a provisional WHO drug name, and prepared a new clinical trial batch for release in September 2026.
- HMBD-002 granted provisional WHO international non-proprietary name
- New drug batch manufactured for clinical trial starting September 2026
- Entitlement offer raised $2.2 million to advance HMBD-002 development
- Positive clinical and preclinical data presented at AACR and ASCO conferences
- Company ends quarter with $4.05 million cash and 3.9 quarters runway
HMBD-002 Receives Provisional WHO Drug Name
Percheron Therapeutics has taken a symbolic step forward in its oncology program with the World Health Organization granting a provisional International Non-Proprietary Name (pINN) of ‘minperstobart’ to its lead drug candidate HMBD-002. This designation, expected to be confirmed in the first half of 2027, marks the transition of the drug from a coded experimental compound to a recognised pharmaceutical entity. Such naming is a critical milestone before commercial branding and signals the drug’s progression into mid-stage clinical development.
New Drug Batch Ready for Upcoming Clinical Trial
Building on its clinical momentum, Percheron completed manufacturing a new batch of HMBD-002 drug substance in June 2026, with final vialled product anticipated to be released by September. This supply is earmarked for a forthcoming clinical trial planned for the second half of 2026, continuing the company’s efforts to advance HMBD-002 beyond its phase I safety and tolerability study. The phase I trial, conducted across six US cancer centres in 48 advanced cancer patients, demonstrated the drug’s safety profile and suggested potential clinical benefits, particularly when combined with Keytruda.
$2.2 Million Raised to Propel Development
Percheron strengthened its financial position through a non-renounceable entitlement offer completed earlier this year, raising approximately $2.2 million before costs. Eligible shareholders subscribed to two new shares for every five held at a price of $0.005, with attached unlisted options exercisable at $0.01 over two years. The shortfall was placed with sophisticated and institutional investors, managed by Blue Ocean Equities and Cygnet Capital. The capital injection is designated to fund the HMBD-002 clinical program and general working capital, underpinning the company’s runway of nearly four quarters at current expenditure levels.
Scientific Engagement at Major Oncology Conferences
Percheron leveraged premier scientific platforms to showcase its HMBD-002 data, presenting posters at the American Association for Cancer Research (AACR) Annual Meeting in San Diego and the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The AACR presentation highlighted the phase I study results, while the ASCO presentation featured new preclinical research from a collaboration with QIMR Berghofer, focusing on VISTA expression patterns in triple-negative breast cancer. This work, led by immunotherapy expert Professor Sudha Rao, is intended to guide future clinical trial designs in that challenging cancer subtype.
Financial Position and Operational Cash Flow
Percheron closed the quarter with $4.05 million in cash, up from $3.10 million at the previous quarter’s end, reflecting the recent capital raise. Operating cash outflows totalled $1.05 million, with research and development expenses accounting for $0.43 million. Payments to related parties, including directors’ fees and salaries, amounted to approximately $0.21 million. The company’s reported funding runway stands at 3.9 quarters, assuming steady expenditure. This financial footing supports the company’s goal of advancing HMBD-002 into the next phase of clinical testing later this year.
Bottom Line?
Percheron’s progress with HMBD-002 is tangible, but the coming months will test whether clinical momentum and capital management align to sustain development beyond mid-2027.
Questions in the middle?
- Will the confirmation of the WHO’s INN for minperstobart influence partnership or licensing opportunities?
- How will the upcoming clinical trial data impact investor confidence and Percheron’s valuation?
- What strategic moves might Percheron pursue to extend its funding runway beyond the current 3.9 quarters?